Table 4 |
||||||||||||||||
|
Scintigraphic identification of breast carcinoma in situ with 99mTc-(V)DMSA and 99mTc-Sestamibi: classification of the studied population (n = 102) according to the histological diagnosis and the scintimammographic criterion set for ductal carcinoma in situ/lobular carcinoma in situ (DCIS/LCIS) |
||||||||||||||||
|
Malignant lesions (n = 46) |
Benign lesions (n = 56) |
|||||||||||||||
|
|
||||||||||||||||
|
Histology |
Carcinoma in situ, alone, or with invasive component (DCIS/LCIS ± IDC/ILC) (n = 20) |
Invasive carcinoma (IDC/ILC) (n = 26) |
Lesions with usual type, or atypical hyperplasia (UTH/ATH) (n = 14) |
Lesions without hyperplasia (fibrosis, adenosis and ductal dilatation) (n = 42) |
||||||||||||
|
Radiotracer |
99mTc-(V)DMSA (n = 19) |
99mTc-Sestamibi (n = 13) |
99mTc-(V)DMSA (n = 25) |
99mTc-Sestamibi (n = 20) |
99mTc-(V)DMSA (n = 14) |
99mTc-Sestamibi (n = 14) |
99mTc-(V)DMSA (n = 14) |
99mTc-Sestamibi (n = 28) |
||||||||
|
Results (-) (n = 28) |
(+) (n = 18) |
(-) (n = 1) |
(+) (n = 6) |
(-) (n = 7) |
(+) (n = 2) |
(-) (n = 23) |
(+) (n = 0) |
(-) (n = 20) |
(+) (n = 10) |
(-) (n = 4) |
(+) (n = 6) |
(-) (n = 8) |
(+) (n = 0) |
(-) (n = 14) |
(+) (n = 0) |
|
|
Classification |
TP |
FN |
TP |
FN |
FP |
TN |
FP |
TN |
FP |
TN |
FP |
TN |
FP |
TN |
FP |
TN |
|
|
||||||||||||||||
|
99mTc-(V)DMSA, technetium-99m pentavalent dimercaptosuccinic acid; 99mTc-Sestamibi (99mTc-MIBI), technetium-99m 2-methoxy isobutyl isonitrile; EIC, extensive intraductal component; IDC, invasive ductal carcinoma; ILC, invasive lobular carcinoma; UTH, usual type hyperplasia; ATH, atypical type hyperplasia; (+), positive scan; (-), negative scan; TP, true positive; FN, false negative; FP, false positive; TN, true negative. |
||||||||||||||||
|
Papantoniou et al. Breast Cancer Res 2005 7:R33 doi:10.1186/bcr948 |
||||||||||||||||
